Amid the 'superbug' crisis, a Big Pharma-backed fund scores a meager raise for antibiotics R&D. Is $140M nearly enough?
Years after Big Pharma abandoned the antibiotics space, a small syndicate has raised $140 million to address the looming threat of antimicrobial resistance — but is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
